articleThe LancetMay 1, 2025GREEN OA

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial

ASAshish Sarraju DMDanielle M. BrennanKHKierstyn HaydenASAmanda Stronczek ACAnne C. Goldberg

Cleveland Clinic · Center for Clinical Research (United States) · +6 more institutions

Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

46

total citations

FWCI: 72.88
Percentile: 100%
References: 32

Citations per year

Authors

16

AS
Ashish SarrajuCorresponding
Cleveland Clinic, Center for Clinical Research (United States)
DM
Danielle M. Brennan
Cleveland Clinic, Center for Clinical Research (United States)
KH
Kierstyn Hayden
Cleveland Clinic, Center for Clinical Research (United States)
AS
Amanda Stronczek
AC
Anne C. Goldberg
Washington University in St. Louis

Topics & keywords

Topics

Keywords

Ezetimibe
Placebo
Double blind
Medicine
Reduction (mathematics)
Ldl cholesterol
Fixed-dose combination
Cholesterol

No related works found for this paper.

Funding